The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not antigen-experienced vaccinees
Authors:
- Julie Van CoillieJCJulie Van Coillie
- Tamas PongraczTPTamas Pongracz
- Johann RahmöllerJRJohann Rahmöller
- Hung-Jen ChenHCHung-Jen Chen
- Chiara GeyerCGChiara Geyer
- Lonneke A. van VlughtLVLonneke A. van Vlught
- Jana S. BuhreJBJana S. Buhre
- Tonći ŠuštićTŠTonći Šuštić
- Thijs L. J. van OschTOThijs L. J. van Osch
- Maurice SteenhuisMSMaurice Steenhuis
- Willianne HoepelWHWillianne Hoepel
- Wenjun WangWWWenjun Wang
Preprint
Abstract
The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses. One sentence summary A transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.Keywords
All Related Versions
- Published version: EBioMedicine, 87, 104408.
This publication has 49 references indexed in Scilit:
- A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancyBlood, 2014
- Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activityJournal of Clinical Investigation, 2013
- High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of GlycopeptidesJournal of Proteome Research, 2013
- Mass Spectrometry: Reconnaissance at the Frontiers of BiologyMolecular & Cellular Proteomics, 2012
- Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interfaceJournal of Proteomics, 2012
- The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathwayMolecular Immunology, 2011
- High Throughput Isolation and Glycosylation Analysis of IgG–Variability and Heritability of the IgG Glycome in Three Isolated Human PopulationsMolecular & Cellular Proteomics, 2011
- Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucoseProceedings of the National Academy of Sciences, 2011
- Elucidation of seventeen human peripheral blood B‐cell subsets and quantification of the tetanus response using a density‐based method for the automated identification of cell populations in multidimensional flow cytometry dataCytometry Part B: Clinical Cytometry, 2010
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002